Entries by Citron Research

, ,

Citron Exposes More Undisclosed Relationships at TransDigm

What the Company and Its Analysts Call “A Game” Is Actually Illegal Price Target $140 Citron predicts that after this report makes its rounds, TransDigm’s (NYSE:TDG) days of exploiting and deceiving the Federal Government are numbered. Valeant Pharmaceuticals has recently hit prices that some never thought imaginable. As Citron observes today, at $12 per share, […]

, ,

Express Scripts: Rebate System is a Financial Engineering Kickback Scheme

One company in the healthcare system that deserves to fall to the mighty sword of the new Trump administration is Express Scripts.  (NASDAQ:ESRX) has used their position as the nation’s largest PBM to make itself into “The reason drugmakers sharply raise list prices without a corresponding increase in net price is that PBMs demand higher […]

, ,

Could TransDigm be the Valeant of the Aerospace Industry?

Wall Street:  Be Careful!  President Trump has become to Aerospace what Hillary was to Pharmaceuticals   President Trump has promised to end the long-standing, infuriating tradition of “sticking the US Government with tab”.  He has already made lowering prices for military aircraft a pillar of his transition into office. President Trump has already met with […]